Early research (Phase 1)Study completedNCT00932373
What this trial is testing
Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen
Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 54